Ampio Pharmaceuticals (AMPE) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Ampio Pharmaceuticals (NYSEAMERICAN: AMPE) recently:

• 8/28/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/22/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/16/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/14/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/13/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/12/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/11/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/9/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/8/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/6/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/5/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/3/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/2/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 8/1/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/30/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/29/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/28/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/27/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/25/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/24/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/23/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/21/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/20/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/19/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/17/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/16/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/15/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/13/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/12/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/11/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/9/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/8/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/7/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/6/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/4/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/3/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/2/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/1/2023 – Ampio Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:AMPE opened at $0.18 on Tuesday. The stock’s fifty day simple moving average is $0.24 and its two-hundred day simple moving average is $0.25. Ampio Pharmaceuticals, Inc. has a 1-year low of $0.17 and a 1-year high of $1.90. The stock has a market cap of $2.73 million, a PE ratio of -0.18 and a beta of 1.67.

Get Ampio Pharmaceuticals Inc alerts:

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter.

Institutional Trading of Ampio Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in Ampio Pharmaceuticals by 998.6% in the 2nd quarter. Millennium Management LLC now owns 2,035,413 shares of the specialty pharmaceutical company’s stock worth $342,000 after buying an additional 1,850,138 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Ampio Pharmaceuticals by 20.0% during the 3rd quarter. Vanguard Group Inc. now owns 9,954,092 shares of the specialty pharmaceutical company’s stock valued at $602,000 after purchasing an additional 1,662,127 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Ampio Pharmaceuticals during the 2nd quarter valued at approximately $72,000. Bank of Montreal Can bought a new position in shares of Ampio Pharmaceuticals during the 1st quarter valued at approximately $168,000. Finally, Two Sigma Advisers LP increased its position in shares of Ampio Pharmaceuticals by 304.3% during the 3rd quarter. Two Sigma Advisers LP now owns 432,216 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 325,300 shares during the last quarter. Institutional investors own 3.10% of the company’s stock.

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.

Featured Stories

• Five stocks we like better than Ampio Pharmaceuticals
• What Is Dividend Yield and How Do You Calculate It?
• 3 Reasons High-Yield Bloomin’ Brands is About to Blossom
• The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
• 5 Computer Vision Stocks with a Clear Path to Growth
• Biggest Stock Losers – Today’s Biggest Percentage Decliners
• 3 Reasons Workday Stock Is Setting Up For A New Rally

Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.